Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study

database[Title] 2025-05-14

Summary:

CONCLUSION: This study showed that patients with LR-MDS treated with luspatercept required significantly less HRU than patients treated with ESA. Further research is warranted to evaluate the financial impact of this lower HRU burden.

Link:

https://pubmed.ncbi.nlm.nih.gov/40329816/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=12QQbiNmM99eUQGIX1JjHIKcROC1Vzv4sOS-2S_LNI19uG_Yrk&fc=20220129225649&ff=20250514033645&v=2.18.0.post9+e462414

From feeds:

📚BioDBS Bibliography » database[Title]

Authors:

Brian J Ball, Rui Song, Enrico Zanardo, Lynn Huynh, Manasi Mohan, Megan Pinaire, Derek Tang, Mihran Yenikomshian, Ashley Swanson, Svetlana Gavrilov, Samantha Slaff

Date tagged:

05/14/2025, 03:36

Date published:

05/07/2025, 06:00